DAWEX
Dawex , the leading data exchange technology company, today announced with Kanematsu Corporation and Japan Data Exchange Inc. the launch of JDEX , a Data Exchange Platform to create a large data trading community in Japan, spanning across industry, academia, and government, and contribute to the promotion of a cross-industry and cross-border data exchange environment. The platform, relying on Dawex Data Exchange technology and operated by Kanematsu, will serve the multinational trading corporation’s domestic and foreign network. JDEX platform enables the sourcing, exchange, sharing and commercialization of data products leveraging the platform's advanced features and capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130005371/en/
Emerging as a key component of the data economy, Data Exchanges are now clearly top of the agenda of an increasing number of corporations, public institutions and governments around the world. With new initiatives on frameworks and policies multiplying everywhere such as GAIA-X in Europe, Data Trading Alliance in Japan, the World Economic Forum or the Data Exchange Association (DXA), the market is increasingly being regulated and standardized encouraging the development of trusted cross-border, cross-industry data ecosystems such as JDEX.
Awarded “Technology Pioneer ” and chosen for the Global Future Council on Data Policy by the World Economic Forum in June 2020, Dawex delivered to Kanematsu the means to deploy a powerful data exchange strategy and to create value as the orchestrator of a rich data ecosystem in Japan and abroad.
“Developing the Japan Data Exchange (JDEX) is a crucial part of Kanematsu’s data strategy that we initiated three years ago. By partnering with Dawex, we rely on the most advanced data exchange technology available today to create and support a new data community. The flexibility and sophistication of Dawex solution enables us to offer a secure and trusted environment to data providers and data acquirers and easily address their business needs.” said Mr. Masahiro Harada, Senior Executive Officer, Electronics and Devices Division at Kanematsu Corporation.
“We are very excited to see this realization with Kanematsu coming to fruition and to observe the multiplication of cross-border and cross-industry data exchange initiatives. This results from a strong commitment impulsed by the Japanese government through its regulations, and initiatives such as the Osaka Track, enabling JDEX to build a rich data community. ” stated Laurent Lafaye co-CEO of Dawex.
“Now armed with advanced data infrastructure relying on Dawex technology, and leveraging a mature governance framework, the Japan Data Exchange will unlock the full potential of a growing data ecosystem and set an example for the transition into a data-driven economy.” says Fabrice Tocco, co-CEO of Dawex. “The data marketplace will enable the development of new data models and foster innovation in a trusted and secure environment.”
About Dawex
Dawex, the leading data exchange technology company and the operator of the largest data marketplace, allows organizations to orchestrate data circulation, by sourcing and exchanging data securely, and in full compliance with regulations. Today 12,000+ organizations from 20+ sectors rely on Dawex Global Data Marketplace and Data Exchange Platform solutions to build their data exchange strategy. In 2020, Dawex is named Technology Pioneer by the World Economic Forum. Created in 2015, Dawex is a tech company with offices in France and Canada, expanding business operations to Asia and the Middle East. www.dawex.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005371/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release
Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio
SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release
Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom